Here are four things to know.
1. More than 33 million people suffer from chronic low back pain in the U.S.; approximately 50 percent of opioid prescriptions in the U.S. are for chronic low back pain.
2. The Phase 3 randomized, placebo-controlled trial evaluates an intra-discal injection of Mesoblast’s proprietary allogeneic mesenchymal precursor cell product candidate MPC-06-ID in 404 patients with chronic low back pain due to degenerative disc disease in the U.S. and Australia.
3. The therapy works by injecting mesenchymal precursor cells directly into damaged discs between the spine’s vertebrae; each dose contains around 6 million cells, which are intended to reduce inflammation and secrete factors to help rebuild damaged tissue.
4. MPC-06-ID is being assessed for whether it can alleviate pain and improve function in patients who do not receive adequate relief from standard therapies such as nonsteroidal anti-inflammatory drugs, epidural steroid injections or opioids.
More articles on biologics:
Global orthobiologics market to exceed $5.5B in 2019: 4 highlights
DiscGenics reveals positive preclinical results for regenerative spine therapy — 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.